A total of 438 confirmed and probable cases of meningococcal disease were reported in 2023, the most US cases reported since ...
The algorithm was roughly 3% more accurate than the relevant diagnostic code and less biased toward certain populations, the ...
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...
Hosted on MSN19h
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call TranscriptThis strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...
(Schnirring, 11/12) Novavax yesterday announced that the US Food and Drug Administration (FDA) has released a clinical hold on its new drug application for its COVID-flu combination and standalone flu ...
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback